These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16760291)

  • 1. From bio-molecular and technology innovations to clinical practice: focus on ovarian cancer.
    Legge F; Ferrandina G; Scambia G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii46-8. PubMed ID: 16760291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis.
    Xiao Y; Bi M; Guo H; Li M
    EBioMedicine; 2022 May; 79():104001. PubMed ID: 35439677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
    Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
    Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
    Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].
    Petri AL; Høgdall E; Engelholm SA; Christensen IJ; Kjaer SK; Høgdall CK
    Ugeskr Laeger; 2007 Aug; 169(33):2614-9. PubMed ID: 17725906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
    BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer.
    Risum S; Høgdall E; Engelholm SA; Fung E; Lomas L; Yip C; Petri AL; Nedergaard L; Lundvall L; Høgdall C
    Int J Gynecol Cancer; 2009 Dec; 19(9):1535-8. PubMed ID: 19955932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellites: perspectives and potentials of mass spectrometric analysis.
    van den Boom D; Jurinke C; McGinniss MJ; Berkenkamp S
    Expert Rev Mol Diagn; 2001 Nov; 1(4):383-93. PubMed ID: 11901853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer in the proteomics era.
    Annunziata CM; Azad N; Dhamoon AS; Whiteley G; Kohn EC
    Int J Gynecol Cancer; 2008; 18 Suppl 1():1-6. PubMed ID: 18336391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS.
    Cadron I; Van Gorp T; Moerman P; Waelkens E; Vergote I
    Methods Mol Biol; 2011; 755():155-63. PubMed ID: 21761301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to the detection of ovarian cancer.
    Høgdall E
    Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural activities are unfavorable for the prognosis of ovarian cancer through mRNA expression analysis.
    Yang L; Bie L; Sun L; Yue Y
    Biomark Med; 2019 Jun; 13(8):663-673. PubMed ID: 30982327
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular diagnostics of ovarian cancer using proteome techniques].
    Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
    Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
    El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
    Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of differential proteins in lung adenocarcinoma using laser capture microdissection combined with liquid chip-mass spectrometry technology.
    Bu LN; Yang SY; Li FT; Shang WL; Zhang W; Huo SF; Nan YD; Tian YX; DU J; Lin XL; Liu YF; Lin YR; Rong BX
    Chin Med J (Engl); 2010 Nov; 123(22):3309-13. PubMed ID: 21163136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
    Boyce EA; Kohn EC
    Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of proteomic analysis to monitor responses to biological therapies.
    Espina V; Dettloff KA; Cowherd S; Petricoin EF; Liotta LA
    Expert Opin Biol Ther; 2004 Jan; 4(1):83-93. PubMed ID: 14680471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
    Cadron I; Van Gorp T; Amant F; Vergote I; Moerman P; Waelkens E; Daemen A; Van De Plas R; De Moor B; Zeillinger R
    Anticancer Res; 2009 Apr; 29(4):1039-45. PubMed ID: 19414343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.
    Fu LL; Li CJ; Xu Y; Li LY; Zhou X; Li DD; Chen SX; Wang FG; Zhang XY; Zheng LW
    Crit Rev Eukaryot Gene Expr; 2017; 27(2):183-195. PubMed ID: 28845767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.